Company Background

• ReSync was founded based on hundreds of conversations with companies at the forefront of AI-enabled drug discovery, and their learnings from building infrastructure for closed-loop, automated operations.
• We learned that while all organizations were motivated to add AI tools to their workflows, integrating models, storing data, and permissioning access were creating months to years of new work for teams.
• Our team wants to make AI-enabled innovation accessible to every company, regardless of their starting point.

Solution Summary

• We’ve built a platform for small molecule discovery teams to centralize their communication, data, and computational tools.
• Our platform enables teams big and small to run design-make-test-analyze (DMTA) cycles efficiently by running large-scale virtual screens, tracking experimental workflows, and visualizing progress – all without scaling a computational team.
• ReSync curates top open source models and partners to make running AI tools within your DMTA cycle simple, removing the need to write any code or hire an engineering team.
• Our unified dashboards allow users to see data-rich visualizations of docking, tabular data, chemical structures, and more directly in their browser – no downloads required.

Case Study

• For a mid-size biotech company, ReSync helped a VP of Medicinal Chemistry gain visibility into chemists’ designs across her organization.
• Instead of emailed ChemDraw files, all virtual structures are registered and described on the ReSync platform.
• The customer is now able to run Docking simulations themselves and view results instantly, instead of making emailed requests to a computational CRO, then waiting days for the results to be sent back.
• During an evaluation, the biotech company found ReSync saved almost a full day a week in time spent searching for data or tracking requests for computational and experimental work.

Partnership Opportunities

• Biotechs, Pharma, Academics, and CROs can all be users of the @ReSync platform. We’re powerful for multi-team collaborations, including Joint Ventures, Consortiums, and multi-site organizations.
• Building predictive or generative models for small molecule drug discovery? Reach out to us at partnerships@resync.bio for more information on how our distribution network can help grow usage of your models.

About Merck Digital Sciences Studio:  

The Merck Digital Sciences Studio (MDS Studio or MDSS) is a collaboration between Merck, the Merck Global Health Innovation Fund, Northpond Ventures, McKesson Ventures, Microsoft for Startups, and the New Jersey Innovation Institute, a New Jersey Institute of Technology (NJIT) subsidiary. The 10-month startup accelerator program empowers members and enables the generation of innovative digital technologies for drug discovery and development through hands-on mentorship, connection opportunities with industry-leading partners, and training in an active entrepreneurial setting. Through the accelerator program, these startups will have access to workshops, coaching, office space, and Microsoft for Startups resources, including up to $150,000 Azure Cloud computing credits. 

The post Revolutionizing Drug Discovery: How ReSync Bio is Simplifying AI for Scientists appeared first on NJII.

Addressing a Critical Challenge in Drug Development 

The pharmaceutical industry faces a staggering challenge: over 90% of novel drug candidates fail during human clinical trials. Often, these failures can be traced to limitations in preclinical animal studies, which struggle to accurately predict human outcomes. Moreover, the traditional methods of designing these studies remain slow, manual, and outdated, with researchers relying on limited literature analysis to inform billion-dollar decisions. 

Led by CEO Ian Levine, ModernVivo’s innovative approach tackles this head-on. The company’s AI-enabled software helps research scientists design preclinical animal models to accelerate project timelines, reduce development costs, and identify more effective therapeutics. This solution not only addresses the inefficiencies of manual study design but also promotes ethical research practices by minimizing the use of animals in experiments. 

Solution Overview 

• ModernVivo has developed an AI-enabled software suite that revolutionizes the way in vivo models are designed by taking a data-driven approach. This allows for rapid development of experimental protocols, and can aid in the identification of more effective therapeutics, earlier on in drug development.  

• ModernVivo’s software allows research scientists at pharmaceutical companies, contract research organizations, and academic institutions to analyze thousands of published articles in a fraction of the time, improving confidence in novel preclinical data.   

• Current functionality focuses on analyzing large quantities of experimental conditions to accelerate study design and lower associated animal costs.  

• Near-term product development focuses on the implementation of the company’s patent-pending technology to identify and prioritize animal study designs that are most representative of the human condition. 

A Vision for the Future 

ModernVivo’s participation in the MDSS program underscores its potential to drive significant advancements in preclinical research. As the company continues to develop its technology and expand its reach, it is poised to play a pivotal role in improving the success rate of novel therapeutics. 

Learn more about ModernVivo and their work on their website.  

About Merck Digital Sciences Studio:   

The Merck Digital Sciences Studio (MDS Studio or MDSS) is a collaboration between Merck, the Merck Global Health Innovation Fund, Northpond Ventures, McKesson Ventures, Microsoft for Startups, and the New Jersey Innovation Institute, a New Jersey Institute of Technology (NJIT) subsidiary. The 10-month startup accelerator program empowers members and enables the generation of innovative digital technologies for drug discovery and development through hands-on mentorship, connection opportunities with industry-leading partners, and training in an active entrepreneurial setting. Through the accelerator program, these startups will have access to workshops, coaching, office space, and Microsoft for Startups resources, including up to $150,000 Azure Cloud computing credits.  

The post Transforming Drug Development with AI: A Spotlight on ModernVivo appeared first on NJII.